logo
搜索
菜单

pharmacoki的搜索结果

当前1/8页
排序: 本月浏览数
Quantification of Ethanol Levels in Zebrafish Embryos Using Head Space Gas Chromatography 10.3791/60766-v 08:22 min
Quantification of Ethanol Levels in Zebrafish Embryos Using Head Space Gas Chromatography
6.14: Clearance Models: Compartment Models 01:25 min
6.14: Clearance Models: Compartment Models
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis 10.3791/60776-v
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System 10.3791/60274-v 07:47 min
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery 10.3791/58485-v 05:44 min
Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs 10.3791/53878-v 10:02 min
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Isolation of Human Hepatocytes by a Two-step Collagenase Perfusion Procedure 10.3791/50615-v 07:09 min
Isolation of Human Hepatocytes by a Two-step Collagenase Perfusion Procedure
Intranasal Administration of CNS Therapeutics to Awake Mice 10.3791/4440-v 07:15 min
Intranasal Administration of CNS Therapeutics to Awake Mice
25.8: Insulin Formulations: Types and Delivery 01:27 min
25.8: Insulin Formulations: Types and Delivery
15.7: Pharmacokinetic–Pharmacodynamic Relationship: Model Components 01:14 min
15.7: Pharmacokinetic–Pharmacodynamic Relationship: Model Components
15.2: Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect 01:28 min
15.2: Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant 01:25 min
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
13.18: Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment 01:08 min
13.18: Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
13.15: Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow 01:26 min
13.15: Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
13.12: Pharmacokinetics in Pediatric Patients: Drug Distribution 01:17 min
13.12: Pharmacokinetics in Pediatric Patients: Drug Distribution
13.2: Drug Dosing: Obese Patients 01:21 min
13.2: Drug Dosing: Obese Patients
12.17: Pharmacokinetics: Drug–Drug Interactions 01:25 min
12.17: Pharmacokinetics: Drug–Drug Interactions
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses 01:25 min
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses 01:25 min
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
9.6: Measurement of Bioavailability: Pharmacokinetic Methods 01:30 min
9.6: Measurement of Bioavailability: Pharmacokinetic Methods
返回顶部